your market intelligence analyst
Search Results
Edit Save
85 results
Takeda Pharmaceutical 06/28/2020 23:00
Osaka, JAPAN, June 29, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the anticipated financial impact from Novartis Europharm Limited’s ("Novartis") withdrawal of the Marketing Authorisation Application ("MAA") for Xiidra® (lifitegrast ophthalmic solution) 5% product ("Xiidra®") in Europe, as posted on the European Medicines Agency’s website on June 26, 2020.
Takeda Pharmaceutical 06/25/2020 04:30
Osaka, Japan, June 25, 2020 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced proposed concurrent offerings of unsecured senior notes to be denominated in U.S. dollars and Euros and issued in multiple tranches. Takeda intends to use the proceeds from the offering primarily to prepay borrowings incurred in connection with the acquisition of Shire plc in 2019, and other outstanding borrowings that Takeda may decide to repay prior to their maturities. Any remaining proceeds will be used for general corporate purposes.
Takeda Pharmaceutical 06/24/2020 03:32
Osaka, JAPAN, June 24, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Company") today announced that at the meeting of its Board of Directors held on June 24, ‎2020, the Board of Directors adopted a new Employee Stock Purchase Plan ("ESPP") and Long Term Incentive Plan ("LTIP") for the Company Group employees overseas, as outlined below.
Takeda Pharmaceutical 06/12/2020 02:30
Osaka and Tokyo, Japan, June 12, 2020 --- Takeda Pharmaceutical Company Limited ("Takeda") (TSE: 4502, NYSE: TAK) and Mitsubishi Corp.-UBS Realty Inc. ("MC-UBS Realty") today announced that they have entered into a basic agreement regarding a comprehensive collaboration for the operation of the Shonan Health Innovation Park ("Shonan iPark"), located in Fujisawa in Kanagawa Prefecture, in order to realize the mission of the Shonan iPark, "Establish a life science ecosystem open to the world."
Takeda Pharmaceutical 05/26/2020 09:00
Osaka, Japan, May 26, 2020 --- Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502, NYSE: TAK) is a key leader of a coalition who today announced that world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups have come together to support the rapid development of potential new therapies for patients with COVID-19.

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities


Strategic Scenarios



  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.